Oncolytic vaccinia virus vaccine: Promising in liver cancer patients
====================================================================

Liver cancer patients treated with a genetically modified smallpox vaccine, called JX-594, showed shrinking tumors and extended survival for more than a year.

JX-594 (also called Pexa-Vac) is being developed by the San Francisco-based company Jennerex Inc. The therapy employs oncolytic tumor viruses, pathogens that infect and destroy cancer cells. In the case of JX-594, researchers used the same strain of virus that is used in the smallpox vaccine, called vaccinia virus, because of its natural ability to replicate in cancer cells. They modified the virus to enhance its cancer-fighting properties. The approach may enhance the tumor-fighting effects of standard treatments such as chemotherapy and radiation, or work alone. While vaccinia virus is similar to smallpox, it cannot cause the disease.

JX-594 is being tested in patients with advanced hepatocellular carcinoma (HCC). In a recent Phase 2 dose-finding trial, patients received a low or high dose of the vaccine three times during a four-week period. In contrast to tumor response rate and immune endpoints, subject survival duration was significantly related to dose. The 16 patients who received a high dose lived a median 14.1 months after injection, compared with 6.7 months for 14 patients on a low dose. About 35% of those in the high-dose group were alive 18 months later, the study said. Results of the study were recently published in the journal *Nature Medicine*.^1^

"The treatment options for advanced HCC are limited, with few promising agents currently in development," said Dr Tony Reid, professor at the University of California, San Diego, and co- lead author of the paper. „The study highlights the unique possibility of a meaningful survival benefit combined with short-term, transient and manageable side effects."

HCC is a cancer that forms in the liver and can spread to other parts of the body. According to the American Cancer Society, the five-year survival rate for liver cancer patients is about 15%.
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FDA panel endorses quadrivalent influenza vaccines
==================================================

An FDA panel recently approved quadrivalent (four-strain) influenza vaccines, thereby setting the stage for a new influenza market. The decision should be a boon to consumers who suffered through a particularly bad flu season this year and to the two companies that already have such vaccines approved, GlaxoSmithKline (GSK) and AstraZeneca's MedImmune.

The FDA advisory panel on vaccines gave its endorsement to a recent proposal by the WHO that next season's flu vaccines contain two influenza A strains and at least one B strain, according to *The Wall Street Journal.* The quadrivalent vaccines will contain two A and two B strains. The panel suggesteded that the B strain from this season's vaccine be altered to better match the influenza strains that caused disease in the US this year.

While three-strain vaccines will continue to be available, they should be replaced with four-strain versions over time. Including four strains will increase the likelihood of health experts and vaccine manufacturers matching circulating strains with the ones in the vaccine.

GSK got its Fluarix Quadrivalent approved at the end of last year, following the earlier approval of MedImmune's intranasal FluMist Quadrivalent. Sanofi also has an FDA approval pending for a quadrivalent flu vaccine. The FDA endorsement will enable those companies with approved quadrivalents to start taking orders for the next flu season.

Approval for the first meningitis B vaccine
===========================================

At the beginning of this year, the European Commission approved Novartis' meningitis B (MenB) vaccine Bexsero for patients two months of age and older. This is the first time that a vaccine has been approved against meningococcus B bacteria.

Following the EU's decision, all member states may begin evaluating Bexsero for potential inclusion into their national immunization and reimbursement programs. According to a company statement, Novartis is committed to making the vaccine available as soon as possible, without detailing how soon.

EU marketing approval for Bexsero came shortly after *The Lancet* published favorable results of a pivotal Phase 3 clinical trial, including 3630 infants from two months of age.^1^ According to the study results, the vaccine showed both a protective immune response and an acceptable safety profile when given to patients as a three-dose primary series along with routine vaccines. A fourth dose administered at 12 months may contribute to extended protection, researchers found.

The development of Bexsero took some 20 years. It started in the mid-1990s with the sequencing of the genome of *Neisseria meningitidis* by Dr J Craig Venter. Novartis scientists, led by Dr Rino Rappuoli, mined the sequence data to discover dozens of novel proteins that could serve as potential antigens. This approach has been termed reverse vaccinology and has been used since then on several other bacterial vaccines. In the case of Bexsero, the researchers found that no single antigen alone could protect against the diversity of meningitis B strains; however, a combination of antigens could. The four antigens included in Bexsero are Neisserial adhesion A (NadA), Factor H binding protein (fHbp), *Neisseria* heparin binding antigen, and Por A, a protein found in some highly virulent strains of MenB.

MenB accounts for up to 90% of meningococcal disease cases in Europe and more than 80% of meningococcal cases among infants in Canada. Experts predict near-blockbuster sales for the new meningitis vaccine.
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Stallergenes seeks FDA approval for sublingual grass-pollen allergy tablet
==========================================================================

The biopharmaceutical company Stallergenes recently announced that the FDA has accepted for review its Biologics License Application (BLA) for Oralair, a 5-grass pollen extract allergen immunotherapy (AIT) sublingual tablet. Stallergenes is the first pharmaceutical company to file and have FDA acceptance to review a BLA for an AIT sublingual tablet.

"We are delighted about the acceptance of our BLA filing for our tablet in the USA, which is fully consistent with our drive for innovation and is a major step in Stallergenes' international growth strategy. We are looking forward to working with the FDA towards the approval", said Dr Roberto Gradnik, Chief Executive Officer of Stallergenes.

Oralair has been marketed in Europe and in some other international markets (e.g., Australia/New Zealand, Russia, and Canada) since 2008 for the treatment of grass pollen allergy. It is the only sublingual AIT tablet composed of a 5-grass pollen extract, which corresponds to the epidemiological exposure of patients. The tablet consists of five purified and calibrated pollen extracts: Perennial Ryegrass (Lolium perenne), Kentucky Bluegrass (Poa pratensis), Timothy Grass (Phleum pratense), Orchard Grass (Dactylis glomerata) and Sweet Vernal Grass (Anthoxanthum odoratum). The tablet is available for patient self-administration with a pre-coseasonal protocol.

Allergic rhinitis affects 60 million people in the US; the most prevalent allergen is grass pollen. Only 3 million allergy sufferers are currently treated by allergen immunotherapy. An self-administered innovative sublingual treatment, like the one offered by Stallergenes, would be a great improvement to the current standard treatment of care in the US for immunotherapy, which consists of multiple injections of allergens in a supervised medical setting.

Live-attenuated dengue vaccine promising in phase 1
===================================================

A novel candidate dengue vaccine developed by scientists at the NIH was safe and immunogenic in an early-stage clinical trial.

Dengue fever is prevalent in many tropical and subtropical regions of the world. The disease is caused by any of four related viruses (DENV-1, DENV-2, DENV-3 and DENV-4), which are transmitted to humans by Aedes mosquitoes. Infection with one dengue virus results in immunity to that specific virus but not to the other three. Moreover, research shows that the likelihood of severe disease increases when a person is subsequently infected with a different dengue virus. This observation suggests that a dengue vaccine should be tetravalent and protective against all four dengue viruses.

TetraVax-DV, developed by the NIH, is a live-attenuated vaccine. Four versions of the vaccine were tested in a Phase 1 clinical trial, each of them including a different mixture of components designed to protect against all four dengue viruses. The study included 112 healthy adults between 18 and 50 years of age who had not previously been exposed to dengue or related viruses. Participants were randomized into four groups to receive a single subcutaneous injection of one of the tetravalent candidate vaccine combinations. In each group 20 people received the vaccine and eight others received placebo. All four candidate vaccine combinations were found to be safe and immunogenic, inducing antibody responses against each of the dengue viruses. One vaccine combination in particular, TV003, resulted in the most balanced antibody response against the dengue viruses. TV003 induced an immune response to at least three viruses in 90% of vaccinated individuals. 45% of vaccinees had antibodies to all four dengue viruses. The study results were recently published in *The Journal of Infectious Diseases*.^1^

"What is promising about TV003 is that it elicited solid antibody responses after just one dose," explained senior study author Dr Stephen Whitehead, who led the development of the vaccine candidates. "Other vaccines in development require two or three injections at higher doses to achieve similar results."

Stakes for developing an effective dengue vaccine are high. According to a recent WHO report, dengue ranked as the fasted spreading vector-borne viral disease in 2012, with an epidemic potential in the world. Over the past 50 years, a 30-fold increase in disease incidence has been registered. Various studies report anywhere from 50 million to 100 million people contracting dengue fever each year.

According to the Dengue Vaccine Initiative, five vaccine candidates are in clinical trials, with several more in advanced development. Sanofi Pasteur's tetravalent dengue vaccine, the leading candidate dengue vaccine in development, is being tested in two Phase 3 trials in Asia and Latin America. Then there is NIH's live-attenuated candidate vaccine described above, which has been licensed to four developing country manufacturers. The most advanced of these licensees is the Butan Institute in São Paulo, Brazil, whose vaccine is entering Phase 2 trials. Merck is working on a subunit vaccine, and GSK has a purified inactivated vaccine, both in Phase 1. Inviragen's live attenuated vaccine has entered Phase 2 clinical trials in Puerto Rico, Colombia, Singapore and Thailand.
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GAVI funds HPV vaccines for girls in developing countries
=========================================================

On the occasion of World Cancer Day on February 4th, the GAVI Alliance announced the approval of pilot human papilloma virus (HPV) vaccine demonstration programs in eight developing countries. More than 180.000 girls in these eight countries are set to receive protection against HPV, the leading cause of cervical cancer.

"Introducing the HPV vaccine in developing countries is the start of a global effort to protect all girls against cervical cancer," said Dr Seth Berkley, GAVI CEO. "Of the 275,000 women who die of cervical cancer annually, 85% live in the world's poorest countries. Cervical cancer is one of the leading cancer killers of women in the developing world."

Ghana, Kenya, Lao PDR, Madagascar, Malawi, Niger, Sierra Leone and Tanzania will become the first countries to receive GAVI support to start HPV vaccine demonstration programmes. These programs will give each country the opportunity to test their ability to put in place the systems that would be needed to roll out the HPV vaccines nationally and to inform their decisions.

While most other vaccines are administered to children under the age of five, HPV vaccines are given to girls between 9 and 13 years of age. These girls may be hard to reach, since many developing countries do not offer routine health services for this age group. Introduction of the vaccine is planned mainly through schools, but also community health programs to reach girls who do not go to school. Ghana, Kenya and Sierra Leone are likely to be the first countries to begin administering HPV vaccinations.

By 2015, GAVI plans to support more than 20 countries to vaccinate approximately one million girls with HPV vaccines through pilot projects. By 2020, more than 30 million girls are expected to have been vaccinated in over 40 countries with GAVI support. GAVI-eligible countries that already have systems in place for national rollouts targeting adolescent girls may apply for funding without undertaking demonstration projects.

Merck and GSK are the only two manufacturers who have prequalified HPV vaccines. GAVI has been working with them to secure the most affordable price for the HPV vaccines. Merck has offered to provide its vaccine Gardasil for \$5 per dose, adding up to a total of \$15 for the recommended three dose regimen. While this represents a 64% reduction on the current lowest public price, GAVI hopes to secure an even lower price for the procurement of HPV vaccines to guarantee the sustainability of current and future programs.

First human trials for new superantigen bioterrorism vaccine
============================================================

The biotech company Integrated BioTherapeutics (IBT) recently announced the initiation of a Phase 1 clinical trial testing the safety and immunogenicity of its staphylococcal enterotoxin B (SEB) vaccine STEBVax in healthy adults.

The Phase 1 trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. Conducted at the Center for Vaccine Development at the University of Maryland in Baltimore (MD, USA), the trial is designed to enroll 28 individuals. A superantigen vaccine will be administered to humans for the first time.

"We are extremely pleased to see a decade-long research and development effort, which was heavily supported by the government, reach this critical milestone," said Dr M Javad Aman, IBT President and Chief Scientific Officer. "Safety evaluation of STEBVax is significant as it is the first time a vaccine for such a potent toxin is being tested in humans."

During infection, *Staphylococcus aureus*and *Streptococcus pyogenes* bacteria release superantigens, which have the ability to cause a massive inflammatory response leading to toxic shock. One of the most potent superantigens is SEB, which---when purified ---is considered a potential bioweapon. The proprietary vaccine STEBVax consists of an attenuated form of SEB, and is considered a stand-alone vaccine for biodefense applications. Furthermore, it is also a component of IBT's multivalent vaccine for prevention and treatment of staphylococcal infections in civilian life, which have become a serious public health problem in times of growing antibiotic resistance. The prospective multivalent vaccine in preclinical development at IBT will contain additional toxoids including other superantigens and pore-forming toxins.

Hexyon hexavalent pediatric vaccine recommended for approval
============================================================

Recently, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the 6-in-1 pediatric vaccine Hexyon for marketing authorization. Upon approval Hexyon will be the only fully liquid, ready-to-use hexavalent pediatric vaccine in Europe.

"We welcome the CHMP's positive recommendation," said Dr Jean-Paul Kress, President of Sanofi Pasteur MSD. "It validates the clinical data supporting the vaccine's effective and safe use for infants. Furthermore, its unique ready-to-use formulation will provide healthcare professionals with a simpler, more convenient vaccination process."

The new hexavalent vaccine has been developed by Sanofi Pasteur MSD, and protects infants against diphtheria, tetanus, pertussis (whooping cough), Hepatitis B, poliomyelitis and invasive infections caused by Haemophilus influenzae type b. The vaccine will be commercialized in Western Europe under the brand name Hexyon and in Eastern Europe under the brand name Hexacima.

The combination pediatric vaccine market is dominated by GSK and its Infanrix Hexa. Sanofi's new vaccine Hexyon will be a serious competitor. Its formulation does not require reconstitution prior to administration, thus making administration simpler and faster than with current vaccines. Hexyon will be indicated for primary and booster vaccination of infants from six weeks to 24 months of age in accordance with official recommendations.
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